Brocq et al.6(2007) and Sciré et al.24(2013) also observed the discontinuation risk of anti-TNF therapy to be smaller in patients with AS as compared with the ones with RA, even after controlled for age, sex, disease duration, comorbidities, concomitant use of DMARD, type of anti-TNF drug, and calendar year. This evidence concerns the gene TNF and rheumatoid arthritis.